Solstice banked €19.8M ($21M) in a Series A funding round led by Alven. The investment includes participation from Peak XV Partners, Acrew Capital, Soma Capital, and Schlafender Hase. The capital is earmarked for further product development as the UK-founded firm targets a global client base within the life sciences sector.
The company develops an AI-native platform designed to automate and accelerate marketing workflows for pharmaceutical companies. By automating creative and compliance processes, the platform reportedly reduces drug campaign production timelines from three months to 10 days while ensuring strict adherence to medical and legal regulations.
Pharma marketing is notoriously slow due to heavily regulated approval cycles and the complexity of medical data translation. Solstice addresses these bottlenecks by using generative AI to produce brand-compliant content, allowing pharmaceutical brands to launch new treatments across multiple markets and professional channels with significantly reduced manual overhead.
The round highlights a growing trend in the European ecosystem where specialist AI applications are solving high-friction operational hurdles within the healthcare and life sciences industries.
Originally reported by Tech Funding News.